全文获取类型
收费全文 | 4379篇 |
免费 | 291篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 31篇 |
儿科学 | 104篇 |
妇产科学 | 36篇 |
基础医学 | 621篇 |
口腔科学 | 71篇 |
临床医学 | 285篇 |
内科学 | 1145篇 |
皮肤病学 | 224篇 |
神经病学 | 290篇 |
特种医学 | 117篇 |
外科学 | 968篇 |
综合类 | 12篇 |
预防医学 | 65篇 |
眼科学 | 36篇 |
药学 | 302篇 |
中国医学 | 16篇 |
肿瘤学 | 359篇 |
出版年
2021年 | 55篇 |
2020年 | 42篇 |
2019年 | 58篇 |
2018年 | 83篇 |
2017年 | 57篇 |
2016年 | 78篇 |
2015年 | 72篇 |
2014年 | 88篇 |
2013年 | 117篇 |
2012年 | 188篇 |
2011年 | 196篇 |
2010年 | 105篇 |
2009年 | 80篇 |
2008年 | 164篇 |
2007年 | 183篇 |
2006年 | 165篇 |
2005年 | 166篇 |
2004年 | 180篇 |
2003年 | 186篇 |
2002年 | 212篇 |
2001年 | 205篇 |
2000年 | 186篇 |
1999年 | 152篇 |
1998年 | 57篇 |
1997年 | 35篇 |
1996年 | 35篇 |
1995年 | 42篇 |
1994年 | 40篇 |
1993年 | 33篇 |
1992年 | 116篇 |
1991年 | 115篇 |
1990年 | 122篇 |
1989年 | 139篇 |
1988年 | 79篇 |
1987年 | 110篇 |
1986年 | 76篇 |
1985年 | 85篇 |
1984年 | 69篇 |
1983年 | 50篇 |
1982年 | 29篇 |
1981年 | 24篇 |
1979年 | 42篇 |
1978年 | 34篇 |
1977年 | 29篇 |
1975年 | 23篇 |
1972年 | 23篇 |
1971年 | 27篇 |
1969年 | 28篇 |
1968年 | 23篇 |
1967年 | 28篇 |
排序方式: 共有4682条查询结果,搜索用时 46 毫秒
1.
2.
Satoshi Ebata Ayumi Yoshizaki Takemichi Fukasawa Shunsuke Miura Takehiro Takahashi Hayakazu Sumida Yoshihide Asano Shinichi Sato 《The Journal of dermatology》2019,46(11):1006-1013
Systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) is the most frequent cause of death for SSc but there is still no sufficient treatment available. Although cyclophosphamide (CYC) therapy is a common treatment which has shown statistical efficacy against SSc‐ILD to date, its effects are temporary and not enough. Rituximab (RTX), the anti‐CD20 monoclonal antibody, has recently shown efficacy in many autoimmune diseases. In SSc‐ILD, RTX is also considered to be one of the novel treatment candidates. However, studies of SSc‐ILD in Japanese treated with RTX have only a few case reports. Therefore, in this study, we retrospectively compared nine patients treated with RTX and 30 patients treated with CYC to investigate the efficacy of RTX treatment for Japanese anti‐topoisomerase I‐positive SSc‐ILD patients. At the 24‐month evaluation, the improvement rates of percent predicted of forced vital capacity and percent predicted of diffusing capacity of the lung carbon monoxide in the RTX‐treated group were significantly higher than those in the CYC‐treated group (20.6 ± 8.8% vs 1.1 ± 3.9%; P < 0.05 and 34.0 ± 6.0% vs ?1.5 ± 2.8%; P < 0.01, respectively). In addition, skin thickness scores also showed a marked improvement from 13.5 points before the start of treatment to 5.8 points after 24 months by RTX therapy (P < 0.05). These results suggest that RTX treatment is more effective for Japanese SSc‐ILD patients than CYC treatment. In the future, it is expected that large‐scale clinical trials will show the usefulness of RTX treatment for SSc‐ILD. 相似文献
3.
4.
5.
Satoshi Ebata Ayumi Yoshizaki Takemichi Fukasawa Asako Yoshizaki-Ogawa Yoshihide Asano Kosuke Kashiwabara Koji Oba Shinichi Sato 《The Journal of dermatology》2022,49(1):179-183
The benefit of rituximab (RTX) for systemic sclerosis-associated interstitial lung disease (SSc-ILD) has been shown in previous clinical trials. However, predictors of RTX efficacy have not been clarified. We investigated whether B-cell responsiveness to RTX is related to therapeutic effect. Ten SSc-ILD patients treated with RTX in an independent clinical trial (Japan Registry of Clinical Trials, jRCTs031180373) were included in this analysis. Peripheral B-cell counts were examined retrospectively before RTX administration (baseline) and at 2, 4, 12, and 24 weeks after the first RTX administration, along with percent-predicted forced vital capacity (%FVC) before and 24 weeks after RTX treatment. Relative to baseline, the percentage of residual peripheral blood B cells at 2 weeks after RTX was negatively correlated with the %FVC improvement at the 24-week assessment (r = ?0.41, p = 0.04). In the subgroup with less than 5% B-cell persistence at week 2, %FVC at the 24-week assessment was significantly improved compared to baseline (p = 0.02). In another subgroup with more than 5% residual B cells, %FVC was not significantly different after 24 weeks compared to baseline (p = 0.41). In conclusion, the removal rate of B cells after 2 weeks of RTX treatment may be a useful surrogate marker of subsequent SSc-ILD improvement. 相似文献
6.
Manabu Fujimoto Jun Asai Yoshihide Asano Takayuki Ishii Yohei Iwata Tamihiro Kawakami Masanari Kodera Masatoshi Abe Masahiro Amano Ryuta Ikegami Taiki Isei Zenzo Isogai Takaaki Ito Yuji Inoue Ryokichi Irisawa Masaki Ohtsuka Yoichi Omoto Hiroshi Kato Takafumi Kadono Sakae Kaneko Hiroyuki Kanoh Masakazu Kawaguchi Ryuichi Kukino Takeshi Kono Monji Koga Keisuke Sakai Eiichi Sakurai Yasuko Sarayama Yoichi Shintani Miki Tanioka Hideaki Tanizaki Jun Tsujita Naotaka Doi Takeshi Nakanishi Akira Hashimoto Minoru Hasegawa Masahiro Hayashi Kuninori Hirosaki Hideki Fujita Hiroshi Fujiwara Takeo Maekawa Koma Matsuo Naoki Madokoro Sei-Ichiro Motegi Hiroshi Yatsushiro Osamu Yamasaki Yuichiro Yoshino Andres James LE Pavoux Takao Tachibana Hironobu Ihn Japanese Dermatological Association Guidelines 《The Journal of dermatology》2020,47(10):1071-1109
The Japanese Dermatological Association prepared guidelines focused on the treatment of skin ulcers associated with connective tissue disease/vasculitis practical in clinical settings of dermatological care. Skin ulcers associated with connective tissue diseases or vasculitis occur on the background of a wide variety of diseases including, typically, systemic sclerosis but also systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid arthritis (RA), various vasculitides and antiphospholipid antibody syndrome (APS). Therefore, in preparing the present guidelines, we considered diagnostic/therapeutic approaches appropriate for each of these disorders to be necessary and developed algorithms and clinical questions for systemic sclerosis, SLE, dermatomyositis, RA, vasculitis and APS. 相似文献
7.
Naohiko Aozasa Masaru Hatano Ryosuke Saigusa Kouki Nakamura Takehiro Takahashi Tetsuo Toyama Hayakazu Sumida Zenshiro Tamaki Hisataka Maki Shun Minatsuki Issei Komuro Shinichi Sato Yoshihide Asano 《The Journal of dermatology》2020,47(6):609-614
Endothelial dysfunction is a hallmark of vasculopathy associated with systemic sclerosis (SSc). Reactive hyperemia peripheral arterial tonometry is a rapid and non-invasive technique to assess peripheral microvascular endothelial function by measuring changes in digital pulse volume during reactive hyperemia. Low scores of the reactive hyperemia index (RHI) imply an impaired vasodilatory response and, accordingly, impaired endothelial and vascular health. To investigate the clinical significance of the RHI in SSc patients, RHI values were measured in 43 SSc patients and 10 healthy controls. In diffuse cutaneous SSc (dcSSc) patients, RHI values were significantly decreased compared with healthy controls, and inversely correlated with disease duration. In total SSc patients, there was a significant inverse correlation between RHI values and skin score, and interstitial lung disease was associated with the decrease in RHI values. Among vascular symptoms, the current and past history of digital ulcers was seen more frequently in patients with decreased RHI values than in those with normal RHI values. Although no SSc patients had pulmonary arterial hypertension, an inverse correlation was evident between RHI values and mean pulmonary arterial pressure measured by right heart catheterization. These results indicate that the decrease in RHI values is associated with skin fibrosis, interstitial lung disease, digital ulcers and pulmonary vascular involvement leading to pulmonary arterial hypertension, supporting the canonical idea that endothelial dysfunction is a critical event underlying the development of tissue fibrosis and vascular complications in SSc. 相似文献
8.
Nirmeen A. Megahed Kei Kohno Ayako Sakakibara Ahmed E. Eladl Ahmed A. Elsayed Chun‐Chieh Wu Yuka Suzuki Taishi Takahara Seiichi Kato Shigeo Nakamura Akira Satou Naoko Asano 《Pathology international》2019,69(12):697-705
Anaplastic variant (av) of diffuse large B‐cell lymphoma (DLBCL) is morphologically defined in the 2017 World Health Organization classification, but still an enigmatic disease in its clinicopathologic distinctiveness, posing the differential diagnostic problem from gray zone lymphoma (GZL) and classic Hodgkin lymphoma (cHL). Thirty‐one cases previously diagnosed as avDLBCL were reassessed. Of these, 27 (87%) and 4 (13%) were node‐based and extranodal diseases, respectively. They were further reclassified into nodal avDLBCL (n = 18), nodal CD30+ DLBCL with T‐cell/histiocyte‐rich large B‐cell lymphoma‐like features (CD30+ DLBCL‐THRLBCL) (n = 6), GZL with features intermediate between DLBCL and cHL (n = 3) and CD30+ extranodal DLBCL, NOS (n = 4). The nodal avDLBCL cases had a sheet‐like proliferation of large cells and/or Hodgkin/Reed‐Sternberg (HRS)‐like cells in 12 (67%) notably with a sinusoidal pattern in 16 (89%). They showed an expression of CD20 and/or CD79a in all and CD30 in 15 of 18. All of them were negative for PD‐L1 on tumor cells, although HRS‐like cells showed negativity or partial loss of other B‐cell markers to varying degrees. The present study highlighted the distinctiveness of the nodal avDLBCL with sinusoidal pattern, but without neoplastic PD‐L1 expression, which provide refined diagnostic criteria for a more precise pathologic and clinical characterization of this disease. 相似文献
9.
10.
Masaya Sekimizu Akihiko Yoshida Sachiyo Mitani Naofumi Asano Makoto Hirata Takashi Kubo Fumito Yamazaki Hiromi Sakamoto Mamoru Kato Naohiro Makise Taisuke Mori Naoya Yamazaki Shigeki Sekine Ichiro Oda Shun‐ichi Watanabe Hiroaki Hiraga Tsukasa Yonemoto Teruya Kawamoto Norifumi Naka Yuki Funauchi Yoshihiro Nishida Kanya Honoki Hirotaka Kawano Hiroyuki Tsuchiya Toshiyuki Kunisada Koichi Matsuda Katsunori Inagaki Akira Kawai Hitoshi Ichikawa 《Genes, chromosomes & cancer》2019,58(6):373-380
Granular cell tumors (GCTs) are rare mesenchymal tumors that exhibit a characteristic morphology and a finely granular cytoplasm. The genetic alterations responsible for GCT tumorigenesis had been unknown until recently, when loss‐of‐function mutations of ATP6AP1 and ATP6AP2 were described. Thus, we performed whole‐exome sequencing, RNA sequencing, and targeted sequencing of 51 GCT samples. From these genomic analyses, we identified mutations in genes encoding vacuolar H+‐ATPase (V‐ATPase) components, including ATP6AP1 and ATP6AP2, in 33 (65%) GCTs. ATP6AP1 and ATP6AP2 mutations were found in 23 (45%) and 2 (4%) samples, respectively, and all were truncating or splice site mutations. In addition, seven other genes encoding V‐ATPase components were also mutated, and three mutations in ATP6V0C occurred on the same amino acid (isoleucine 136). These V‐ATPase component gene mutations were mutually exclusive, with one exception. These results suggest that V‐ATPase function is impaired in GCTs not only by loss‐of‐function mutations of ATP6AP1 and ATP6AP2 but also through mutations of other subunits. Our findings provide additional support for the hypothesis that V‐ATPase dysfunction promotes GCT tumorigenesis. 相似文献